

**REMARKS**


**Rejections under 35 USC §103**

Claims 23 and 51-61 were rejected under 35 USC §103 as unpatentable over the Kim and Peacock reference in view of the Brunschwig et al. reference. Applicant respectfully traverses this rejection as it may pertain to the amended claims.

As amended, Claim 23 is directed to a cell having a lipidated protein incorporated into the cell membrane, and a fusion protein bound thereto. The fusion protein comprises a first and second domain, the second domain having a *trans* signaling and/or adhesion function. It is submitted that the cited references do not show a fusion protein having these functions attached via a lipidated protein. It is further submitted that it would not be obvious to combine these references, as has the Examiner, to arrive at the present invention, for the reasons previously submitted in the Declaration of Mark Tykocinski, filed in the parent case, now US Patent 6316256. A copy of this declaration is enclosed for your convenience. Applicant respectfully submits that Claim 23, and the claims depending therefrom, Claims 51-61, are not obvious and requests withdrawal of this rejection.

As all outstanding issues have been addressed, Applicant respectfully submits Claims 23 and 51-61 are in condition for allowance; such action is respectfully requested at an early date.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Debra Z. Anderson". The signature is fluid and cursive, with the first name "Debra" and last name "Anderson" clearly distinguishable.

Debra Z. Anderson, Reg. No. 44,506  
Eckert Seamans Cherin & Mellott, LLC  
600 Grant Street, 44<sup>th</sup> Floor  
Pittsburgh, PA 15219  
Attorney for Applicant

(412) 566-1910



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Group Art Unit 1642  
MARK L. TYKOCINSKI ET AL. : Examiner Alana M. Harris, Ph.D.  
Serial No. 09/476,828 :  
Filed January 3, 2000 : Attorney Docket No. 285332-00002  
METHODS FOR PROTEIN :  
TRANSFER :

RECEIVED

NOV 21 2003

TECH CENTER 1600/2900

DECLARATION OF MARK L. TYKOCINSKI

I, Mark L. Tykocinski, being duly sworn hereby declare as follows:

1. I have a B.A. Degree in Biology from Yale University, awarded in 1974, and an M.D. from New York University, awarded in 1978.
2. From 1978 to 1979, I was a resident in the Department of Internal Medicine at Columbia-Presbyterian Medical Center (New York, NY); from 1979 to 1981 I was an Anatomic Pathology resident in the Department of Pathology at New York University (New York, NY); and from 1981 to 1983 I was a Medical Staff Fellow in the Laboratory of Immunogenics, National Institute of Allergy and Infectious Diseases, National Institutes of Health (Bethesda, MD);
3. From 1983 to present, I have held various faculty appointments as listed in Exhibit A, most recently as Simon Flexner Professor and Chair (with tenure), Department of Pathology and Laboratory Medicine, University of Pennsylvania (Philadelphia, PA).
4. I am a member in the professional societies listed in Exhibit B.
5. I have received the awards and honors listed in Exhibit C.
6. I am an author of the publications listed in Exhibit D.
7. My various professional activities, including teaching responsibilities, academic committees, executive training programs, seminars and invited lectureships, national and international presentations, editorial positions, organizing roles in scientific meetings, advisory boards and patents are listed in Exhibit E.
8. I am a named inventor on two patents and six patent applications and have an inventor's understanding of the patent system.

9. I am a named inventor on the captioned application. I participated in the preparation of the patent application, and carefully reviewed the application prior to its filing. I have read the previous Office Action issued in this case, and participated in the response to that Office Action. I have read the outstanding Office Action, and have participated in the response to that Office Action, including responding to the rejection made under 35 U.S.C. § 112, second paragraph and the rejection made under 35 U.S.C. § 103.

10. It is my well considered opinion that Claims 1-22 would not be considered indefinite by those skilled in the art, in view of the specification and examples provided therein. Additionally, there are numerous assays and procedures, well-known in the art, for assessing the immunoregulatory function of a protein or peptide, or fragment or derivative thereof. These assays are routine, simple-to-perform, and in many cases, available (such as ELISA) in the form of commercial kits to carry them out, and are widely advertised in any one of a number of immunology journals. Examples of such assays include: 1) monitoring <sup>3</sup>H-thymidine incorporation, as a measure of cellular proliferation (for example, T cell proliferation); 2) monitoring the lysis of <sup>51</sup>Cr-labeled target cells, as a measure of antigen-specific cytolytic activity (for example, for cytotoxic T cells); 3) performing the JAM assay, as another measure of antigen-specific cytolytic activity; and 4) measuring changes in the secretion of pro-inflammatory and other cytokines, as a measure of immune cell activation (for example, dendritic cell or T cell activation).

11. The above-listed assays are only a few of many assays known and widely used in the art. These various assays can be used to determine whether a candidate protein or peptide, or a fragment or derivative thereof, either increases or decreases particular immune responses. It is my well considered opinion, therefore, that one skilled in the art would easily be able to determine which protein or peptide fragments or derivatives would elicit the desired immune response and that Claims 1-22 are not indefinite.

12. It is my well considered opinion that the invention embodied in Claims 1-13, 15 and 18-21 would not be obvious to one skilled in the art, in view of the references cited. Kim and Peacock disclose a method of antibody transfer using chemically lipidated protein A; Brunschwig discloses a method of transferring various proteins using GPI to attach proteins to the cell surface. Significantly, the GPI moieties are attached to the proteins by the cell's natural synthetic machinery. These references cannot be combined to arrive at the present invention.

13. Even with knowledge of costimulator-GPI protein transfer, as described in Brunschwig et al., one skilled in the art would not be motivated to combine this

method with the non-GPI antibody transfer method of Kim and Peacock. Among the reasons for this are the following:

i) GPI proteins were known to segregate into cholesterol-rich membrane microdomains, but this was not known to be the case for palmitated protein A. This is quite significant, since it is generally believed that activation of T cells by antigen-presenting cells requires clustering of *trans* signaling molecules into microdomains, which in turn aggregate at the critical antigen-presenting cell:T cell contact sites. See, for example, Moran, M., and Miceli, M.C., "*Engagement of GPI-linked CD48 contributes to TCR signals and cytoskeletal reorganization: a role for lipid rafts in T cell activation*", *Immunity* 9:787, 1998, in which the ability of GPI proteins to migrate to microdomains and lipid rafts in the cell membrane is described, and which provides further evidence that surface localization of GPI proteins on both the T cell and APC sides is important in T cell activation. Whereas costimulator-GPI fusion proteins would be expected to segregate into specialized *trans* signaling units in this way, there is no compelling reason to believe *a priori* that costimulator-Fc:palmitated protein A conjugates would similarly do so. The high degree to which GPI fusion proteins are integrated into these surface microdomains is highlighted by the fact that once positioned in these membrane structures, they can even signal in *cis* through their anchoring GPI lipids; palmitated protein A would simply not be able to do this. GPI fusion proteins achieve a topological distribution on the surface membrane that would not necessarily be expected of other membrane-anchoring, even lipidated, proteins.

ii) Whereas costimulator-GPIs are, by definition, a single molecular moiety, the costimulator-Fc:palmitated protein A conjugates of the present invention are comprised of two distinct units. Since the component units of the latter conjugates are each quite large, one would expect these conjugates to project away from the cell surface a considerable distance, and certainly substantially further than costimulator-GPIs project from the cell surface. This complication would dissuade one from turning to costimulator-Fc:palmitated protein A conjugates, with the expectation of topological distortion at the intercellular *trans* signaling interface. Also relevant is the fact that protein A is inherently pentavalent, which would further add to the sheer bulk of the *trans* signaling unit and potentially interfere with its achieving physical proximity with the antigen signaling unit.

iii) The immunoglobulin:palmitated protein A conjugates delivered according to the Kim and Peacock method, as described in their publication, turn out to be relatively short-lived at the cell surface. Hence, one would have been dissuaded from abandoning GPI proteins in favor of short-lived palmitated proteins. As part of the present

invention, the Kim and Peacock procedure was modified by increasing the temperature from 4°C to 37°C; at this higher temperature enhanced membrane stability was achieved.

14. It is my well considered opinion that one skilled in the art could not have predicted that the use of palmitated or otherwise lipidated fusion proteins or peptides, or fragments or derivatives thereof, would retain their *trans* signaling capability, based on the teachings of the references, or on any other teachings.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

4127101  
Date

Mark Tykocinski  
Mark L. Tykocinski

**EXHIBIT A****FACULTY, HOSPITAL AND ADMINISTRATIVE APPOINTMENTS****Faculty Appointments:**

1983-90	Assistant Professor, Department of Pathology, Case Western Reserve University (Cleveland, OH)
1987-90	Assistant Professor of Oncology, (secondary appointment), Case Western Reserve University
1990-95	Associate Professor (with tenure), Department of Pathology, Case Western Reserve University
1990-96	Associate Professor Oncology, (secondary appointment), Case Western Reserve University
1995-98	Professor (with tenure), Department of Pathology, Case Western Reserve University
1995-98	Professor of Oncology (secondary appointment), Case Western Reserve University
1998 -	Adjunct Professor, Department of Pathology, Case Western Reserve University
1998 -	Simon Flexner Professor and Chair (with tenure), Department of Pathology and Laboratory Medicine, University of Pennsylvania (Philadelphia, PA)

**Hospital and Administrative Appointments:**

1983-98	Staff Physician, University Hospitals of Cleveland
1985-91	Participating Physician and Pathology Specialist MetLife HealthCare Network of Ohio, Inc.
1993-98	Director (and Founder), Gene Therapy Program, CWRU Cancer Center
1994-98	Director (and Founder), Gene Therapy Facility, CWRU School of Medicine
1994-98	Director, Molecular Biology Core Facility, Skin Disease Research Center, CWRU
1995-97	Co-Principal Investigator, Phase I clinical trial for gene therapy/immunotherapy of human glioblastoma
1998 -	Chair, Department of Pathology and Laboratory Medicine, University of Pennsylvania
1999 -	Staff Physician, Hospital of the University of Pennsylvania (Philadelphia, PA)
1999 -	Staff Physician, Presbyterian Medical Center (Philadelphia, PA)
1999 -	Staff Physician, Pennsylvania Hospital

- (Philadelphia, PA)
- 1999 - Participating Physician and Pathologist,  
Preferred Health Network (Multi-State)
- 2000 - Clinical Effectiveness and Quality  
Subcommittee—Laboratory Leader, University  
of Pennsylvania Medical Center (Philadelphia,  
PA)
- 2000- Advisory Committee, Program of Excellence in  
Gene Therapy at the University of Pennsylvania  
(Philadelphia, PA)
- 2000- Graduate Group in Immunology, University of  
Pennsylvania Health System (Philadelphia, PA)
- 2000- Universities Associated for Research and  
Education in Pathology, UAREP Board of  
Directors

**EXHIBIT B****MEMBERSHIP - PROFESSIONAL SOCIETIES AND COMMITTEES****National Societies:**

1984 - American Society for Investigative Pathology  
1985 - American Association for Cancer Research  
1985 - International Society of Differentiation  
1985 - National Institutes of Health Alumni Assoc.  
1991 - American Association of Immunologists  
1991 - Marine Biological Laboratory, Member  
1998 - Association of Pathology Chairs  
2000 - American Association of University Pathologists

**Local Societies:**

1989-98 Cleveland Medical Library Association  
1999 - Pennsylvania Association of Pathologists  
1999 - Pennsylvania Medical Society

**National Scientific Committees:**

Member, American Association of Pathologists Ad Hoc Committee on Initiatives in Education, 1990  
Visiting Scholar in Biotechnology, Ohio Academy of Science, 1990  
Ad Hoc Member, NIH Pathology B Study Section, 1990  
Member, NIH Pathology B Study Section, 1991-1996 (Chairman 1994-96)  
Ad Hoc Member, NIH Pathology B AHR M1 study section, 1992  
Ad Hoc grant reviewer for the American Heart Association, 1992  
Ad Hoc grant reviewer for the Israel Science Foundation, 1993  
Ad Hoc Member, NIH Pathology B AHR M2 Study Section, 1993  
Member, Research Services Committee, Marine Biological Laboratory, 1995-96  
Member, Neoplasia Subsection of the American Society for Investigative Pathology, 1995  
Member, Experimental Therapeutics Subcommittee Section on Gene Therapy of the American Association of Cancer Research, 1995  
Ad Hoc Member, NIH Experimental Therapeutics 2 Special Emphasis Panel, 1995  
External Reviewer, Kennedy Institute of Rheumatology for the Arthritis and Rheumatism Council, Chesterfield, Derbyshire, England, 1996  
Member, 1996 Program Committee, American Assoc. for Cancer Research, 1996



Chair, NIH Biological and Physiological Science Special  
Emphasis Panel, ZRGZ, NEP (2), 1996  
Ad Hoc Member, NIH Pathology B Study Section, 1997  
Chair, NIH Experimental Therapeutics Special Emphasis Panel,  
1997  
Ad Hoc Reviewer, New York University 1997 Whitehead  
Fellowships for Junior Faculty in Biological Sciences,  
1997  
Member, NIH Site Visit Team, Tulane Regional Primate  
Research Center, 1997  
Ad Hoc Member, NIH Fellowship Review Committee SSS-1,  
1998  
Chair, NIH Fellowship Review Committee SSS-1, 1998  
Chair, NIH Biological and Physiological Sciences Special  
Emphasis Panel, ZRG2 SSS-1 (1), 1998

Local Scientific Committees:

Member, CWRU Cancer Center Grant Review Committee,  
1986-90  
Member, Molecular Biology Program, CWRU Cancer Center,  
1986-98  
Chairman, Diagnostic Molecular Biology and Planning Search  
Committee, Institute of Pathology, CWRU, 1988-89  
Member, Planning Committee for AIDS Program Project,  
1988-90  
Member, Hematopoietic Cell Program, CWRU Cancer  
Center, 1988-90  
Member, CWRU Recombinant DNA Experimentation Review  
Board, 1988  
Faculty Member, Cell Biology Program, CWRU, 1989-98  
Research Committee liaison to the Dean's Musculoskeletal  
Task Force, CWRU, 1990-91  
Ad Hoc Member, Oncology Task Force, CWRU Cancer  
Center, 1990  
Member, Molecular Virology and AIDS Program, CWRU  
Cancer Center, 1991-98  
Member, Hematopoietic and Immune Cell Biology Program,  
CWRU Cancer Center, 1991-98  
Faculty Member, Cell and Molecular Biology Training  
Program, CWRU, 1992-98  
Faculty Member, Pharmacological Sciences Training  
Program, CWRU, 1992-98  
Member, Brain Tumor Research Working Committee,  
CWRU, 1993  
Faculty Member, Graduate Program in Molecular Virology,  
CWRU, 1993-98  
Faculty Member, Research Oncology Training Grant, CWRU,  
1993-98  
Faculty Member, Immunology Training Grant, CWRU,  
1995-98

Member and Chair, Gene Therapy Facility Advisory  
Committee, CWRU, 1997-98  
Member, ACS Institutional Grant Review Committee,  
CWRU, 1997

**EXHIBIT C**

**AWARDS AND HONORS**

- |         |   |
|---------|---|
| 1993    | Guest Professor, Fourth Military Medical University, Shanghai, China    |
|         | Guest Professor, Second Military Medical University, Xi'an, China       |
| 1994-96 | Chairman, NIH Pathology B Study Section                                 |
| 1995    | Warner-Lambert/Parke-Davis Award  |
|         | (American Society for Investigative Pathology, FASEB)                   |
| 2001-   | Member, Pluto Society – American Association of University Pathologists |

**EXHIBIT D****PUBLICATIONS**

1. Lown, B., **Tykocinski, M.**, Garfein, A., and Brooks. Sleep and ventricular premature beats. *Circulation* 48:691-701, 1973.
2. Wilkinson, J.M., **Tykocinski, M.L.**, Coligan, J.E., Kimball, E.S., and Kindt, T.J. Rabbit MHC antigens: occurrence of non-beta-2-microglobulin associated class I molecules. *Mol. Immunol.* 19:1441-1451, 1982.
3. **Tykocinski, M.**, Schinella, R.A., and Greco, M.A. Fibroblastic reticulum cells in human lymph nodes: an ultrastructural study. *Arch. Path.* 107:418-422, 1983.
4. **Tykocinski, M.**, Schinella, R.A., and Greco, M.A. The pleomorphic cells of advanced disseminated mycosis fungoides: an ultrastructural study. *Arch. Path.* 108:387-391, 1984.
5. **Tykocinski, M.L.** and Max, E.E. CG dinucleotide clusters in MHC genes and in 5' demethylated genes. *Nucl. Acids Res.*, 12:4385-4396, 1984.
6. **Tykocinski, M.L.**, Marche, P.N., Max, E.E., and Kindt, T.J. Rabbit class I MHC genes: cDNA clones define full-length transcripts of an expressed gene and a putative pseudogene. *J. Immunol.* 133:2261-2269, 1984.
7. Marche, P.N., **Tykocinski, M.L.**, Max, E.E., and Kindt, T.J. Structure of a functional rabbit class I MHC gene: similarity to human class I genes. *Immunogenetics* 21:72-82, 1985.
8. Rabson, A.B., Hamagishi, Y., Steele, P.E., **Tykocinski, M.L.**, and Martin, M.A. Characterization of human endogenous retroviral envelope RNA transcripts. *J. Virol.* 56:176-182, 1985.
9. Medof, M.E., Lublin, D.M., Holers, V.M., Ayers, D.J., Getty, R.R., Leykam, J.F., Atkinson, J.P., and **Tykocinski, M.L.** Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. *Proc. Natl. Acad. Sci. (USA)* 84:2007-2011, 1987.
10. Werber, H.I., Emancipator, S.N., **Tykocinski, M.L.**, and Sedor, J.R.: The interleukin I gene is expressed by rat glomerular mesangial cells and is enriched in immune complex glomerulonephritis. *J. Immunol.* 138:3207-3212, 1987.
11. Lublin, D.M., Lemons, R.S., LeBeau, M., Holers, V.M., **Tykocinski, M.L.**, Medof, M.E., and Atkinson, J.P. The gene encoding decay-accelerating factor (DAF) is located in the complement-regulatory locus on the long arm of chromosome 1. *J. Exp. Med.* 165:1731-1736, 1987.

12. Stafford, H.A., **Tykocinski, M.L.**, Lublin, D.M., Holers, V.M., Rosse, W.F., Atkinson, J.P., and Medof M.E. Normal polymorphic variations and transcription of the decay accelerating factor (DAF) gene in paroxysmal nocturnal hemoglobinuria (PNH) cells. *Proc. Natl. Acad. Sci. (USA)* 85:880-884, 1988.
13. Cheung, N.-K., Walter, E., Smith-Mensah, W.H., Ratnoff, W., **Tykocinski, M.L.**, and Medof, M.E. Decay accelerating factor (DAF) protects human tumor cells from complement mediated cytotoxicity *in vitro*. *J. Clin. Invest.* 81:1122-1128, 1988.
14. Hambor, J.E., Hauer, C.A., Shu, H.-K., Groger, R.K., Kaplan, D.R., and **Tykocinski, M.L.** Use of an Epstein-Barr virus episomal replicon for anti-sense RNA-mediated gene inhibition in a human cytotoxic T cell clone. *Proc. Natl. Acad. Sci. (USA)* 85:4010-4014, 1988.
15. **Tykocinski, M.L.**, Shu, H.-K., Ayers, D.J., Walter, E.I., Getty, R.R., Groger, R.K., Hauer, C.A., and Medof, M.E. Glycolipid reanchoring of T-lymphocyte CD8 using decay-accelerating factor mRNA's 3' end sequence. *Proc. Natl. Acad. Sci. (USA)* 85:3555-3559, 1988.
16. Hambor, J.E., **Tykocinski, M.L.**, and Kaplan, D.R. Functional consequences of anti-sense RNA-mediated inhibition of CD8 surface expression in a human cytotoxic T cell clone. *J. Exp. Med.* 168:1237-1245, 1988.
17. Hauer, C., Getty, R., and **Tykocinski, M.** Epstein-Barr virus episome-based promoter function in human myeloid cells. *Nucl. Acids Res.* 17:1989-2003, 1989.
18. Groger, R.K., Morrow, D., and **Tykocinski, M.L.** Directional antisense and sense cDNA cloning using Epstein-Barr virus episomal expression vectors. *Gene* 81:285-294, 1989.
19. Fasel, N., Rousseaux, M., Schaerer, E., Medof, M.E., **Tykocinski, M.L.**, and Bron, C. *In vitro* attachment of glycosyl-inositol phospholipid anchor structures to mouse Thy-1 antigen and human decay-accelerating factor. *Proc. Natl. Acad. Sci. (USA)* 86:6858-6862, 1989.
20. Kaplan, D.R., Hambor, J.E., and **Tykocinski, M.L.** An immunoregulatory function for the CD8 molecule. *Proc. Natl. Acad. Sci. (USA)* 86:8512-8515, 1989.
21. Hambor, J.E., Kaplan, D.R., and **Tykocinski, M.L.** CD8 functions as an inhibitory ligand in mediating the immunoregulatory activity of CD8-positive cells. *J. Immunol.* 145:1646-1652, 1990.
22. Hambor, J.E., Weber, M., **Tykocinski, M.L.**, and Kaplan, D.R. Regulation of allogeneic responses by expression of CD8 on stimulator cells. *Int. Immunol.* 2:879-883, 1990.
23. Trojan, J., Blossey, B.K., Johnson, T.R., Rudin, S.D., **Tykocinski, M.**, Ilan, J., and Ilan J. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. *Proc. Natl. Acad. Sci. (USA)* 89:4874-4878, 1992.

24. LeBlanc, A.C., Kovacs, D.M., Chen, H.Y., Villare, F., **Tykocinski, M.**, Autilio-Gambetti, L., and Gambetti, P. Role of amyloid precursor protein (APP): Study with antisense transfection of human neuroblastoma cells. *J. Neuroscience Res.* 31:635-645, 1992.
25. Hocevar, B.A., Morrow, D.M., **Tykocinski, M.L.**, and Fields, A.P. Protein kinase C isotypes in human erythroleukemia cell proliferation and differentiation. *J. Cell Science* 101:671-679, 1992.
26. Trojan, J., Johnson, T.R., Rudin, S.D., Ilan, J., **Tykocinski, M.**, and Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. *Science* 259:94-97, 1993.
27. **Tykocinski, M.L.**, and Kaplan, D.R. CD8-dependent immunoregulation: prospects for anti-rejection therapies based upon CD8 modification of alloantigen-presenting cells. *Kidney Int.* 43 (Suppl. 39):S120-S123, 1993.
28. Talento, A., Nguyen, M., Law, Podack, E.R., **Tykocinski, M.L.**, et al. Transfection of mouse CTL with an antisense granzyme A vector reduces lytic activity. *J. Immunol.*, 149(12):4009-4015, 1992.
29. Liang, X., Tang, M., Zamb, T.J., Babiuk, L.A., Rosenberry, T.L., and **Tykocinski, M.L.** Expression of glycoprotein gIII-human decay accelerating factor chimera on a bovine herpesvirus 1 (BHV 1) virion via a glycosyl phosphatidylinositol-based membrane anchor. *J. Virology*, 67:8:4896-4904, 1993.
30. Yen, A., Forbes, M.E., Varvayanis, S., **Tykocinski, M.L.**, Groger, R.K. and Platko, J.D. C-FMS dependent HL-60 cell differentiation and regulation of RB gene expression. *J. Cell. Physiol.* 157(2):379-91, 1993.
31. Singh, N., Zoeller, R., **Tykocinski, M.**, Lazarow, P., and Tartakoff, A. The addition of lipid substituents of mammalian protein glycosyl-phosphoinositol anchors. *Mol. Cell Biol.* 14:21-31, 1994.
32. Weber, M.C., Groger, R.K., and **Tykocinski, M.L.** Membrane-anchored glycosylphosphatidylinositol-modified M-CSF can function as an artificial adhesin. *Experimental Cell Research* 210:107-112, 1994.
33. Weber, M., and **Tykocinski, M.L.** Stromal cell blockade of human leukemic cellular differentiation. *Blood*, 83(8):2221-2229, 1994.
34. Huang, J.-H., Greenspan, N., and **Tykocinski, M.L.** Alloantigenic recognition of artificial glycosyl-phosphatidylinositol (GPI)-anchored HLA-A2. *Mol. Immunol.*, 31(13): 1017-1028, 1994.
35. Trojan, J., Johnson, T.R., Rudin, S.D., Blossey, B.K., Kelley, K.M., Shevelev, A., Abdul-Karim, F.W., Anthony, D.D., **Tykocinski, M.L.**, Ilan, J., Ilan, Jo. Gene Therapy of Murine Teratocarcinoma: Separate functions for IGF-I and IGF-II in immunogenicity and differentiation., *Proc. Natl. Acad. Sci. USA*, 91:6088, 1994.

36. Morrow, D.M., Getty, R.R., Riittinen, L., Seppala, M., and **Tykocinski, M.L.** Hematopoietic placental protein 14 (PP14): An immunosuppressive factor in cells of the megakaryocytic lineage. *Am. J. Pathol.* 145(6) 1485-1495, 1994.
37. Huang, J.-H., Getty, R., Fowler, P., Chisari, F.V., Greenspan, N., and **Tykocinski, M.L.** Protein transfer of functional pre-formed MHC:nominal antigen peptide complexes. *Immunity*, 1:607-613, 1994.
38. Fayen, J., Huang, J.-H., Meyerson, H., Zhang, D., Getty, R., Greenspan, N., and **Tykocinski, M.** Class I MHC alpha-3 domain can function as an independent structural unit to bind CD8. *Mol. Immunology*, 32:267-275, 1995.
39. Brunschwig, E., Levine, E., Trefzer, U., and **Tykocinski, M.L.** Glycosyl-phosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function. *J. Immunol.* 155:5498-5505, 1995.
40. Elkin, M., Shevelev, A., Schulze, E., **Tykocinski, M.L.**, Cooper, M., Ariel, I., Pode, D., Kopf, E., de Groot, N., Hochberg, A. The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma. *FEBS Lett.* 374:57-61, 1995.
41. Matrisian, L.M., **Tykocinski, M.L.** and Padarathsingh, M. Meeting Report: Lessons to be learned from hematopoietic malignancies. *Am. J. Pathol.* 146(5):1519, 1995.
42. Meyerson, H.M., Huang, J.-H., Fayen, J.D., Getty, R.R., Greenspan, N.S., **Tykocinski, M.L.** Functional dissociation of CD8 alpha's Ig homologue and connecting peptide domains. *J. Immunol.* 156:574-584, 1996.
43. **Tykocinski, M.L.** Kaplan, D.R. and Medof, M.E. Antigen-presenting cell engineering: the molecular toolbox. *Am. J. Pathol.* 148:1-16, 1996.
44. Cooper, M.J., Fischer, M., Komitowski, D., Shevelev, A., Schulze, E., Ariel, I., **Tykocinski, M.L.**, Miron, S., Ilan, J., de Groot, N., and Hochberg, A. Developmentally imprinted genes as markers for bladder tumor progression. *J. Urol.* 155:2120-2127, 1996.
45. Singh, N., Liang-L-N, **Tykocinski, M.L.**, and Tartakoff, A.M. A novel class of cell surface glycolipids of mammalian cells. *J. Biol. Chem.* 271:12879-12884, 1996.
46. Medof, M.E., **Tykocinski, M.L.** Surface engineering with GPI-anchored proteins. *FASEB J*, 10:574-586, 1996.
47. Lei, D.C., Kunzelmann, K., Koslowsky, T., Yezzi, M.J., Escobar, L.C., Xu, Z., Ellison, A.R., Rommens, J.M., Tsui, L-C, **Tykocinski, M.** and Gruenert, D.C. Episomal expression of wild-type CFTR corrects cAMP-dependent chloride transport in respiratory epithelial cells. *Gene Therapy*, 3:427-436, 1996.
48. Rachmilewitz, J., and **Tykocinski, M.L.** Differential effects of chondroitin sulfates A and B on monocyte and B-cell activation: Evidence for B-cell activation via a CD44-dependent pathway. *Blood*, 92:223-229, 1998.

49. Weber, M. and **Tykocinski, M.L.** Antisense modulation of the ICAM-1 phenotype of a model human bone marrow stromal cell line. *Exp. Cell Res.*, 244:239-248, 1998.
50. Chen, A., Meyerson, H.J., Salvckar, A., and **Tykocinski, M.L.** Non-glycosylated human B7-1 (CD80) retains the capacity to bind its counter-receptors. *FEBS Letts.*, 428: 127-134, 1998.
51. Kopf, E., Bibi, O., Ayesh, S., **Tykocinski, M.**, Cooper, M., Vitner, K., Khvalevsky, E., Looijenga, L.H.J., de Groot, N., and Hochberg, A. The effect of retinoic acid on the activation of the human H19 promoter by a 3' enhancer. *FEBS Letts.*, 432:123-127, 1998.
52. Fayen, J., Huang, J.-H., Ferrone, S., and **Tykocinski, M.L.** Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events. *Int. Immunol.*, 10:1347-1358, 1998.
53. Miller, R.E., Fayen, J.D. Chakraborty, S., Weber, M.C., and **Tykocinski, M.L.** A receptor for the lipocalin placental protein 14 on human monocytes. *FEBS Letts.*, 436:455-460, 1998.
54. Rachmilewitz, J., Riely, and **Tykocinski, M.L.** Placental protein 14 functions as a direct T-cell inhibitor, *Cell. Immunol.* 191:26-33, 1999.
55. Kopf, E., Bibi, O., Ayesh, S., Ariel, J., Schulze, E., Schneider, T., **Tykocinski, M.L.** Erdmann, V., Laster, M., Holthuisen, E., de Groot, N., and Hochberg, A. The in vivo and in vitro expression of H19 and IGF-2 genes in human bladder carcinoma cell lines.
56. Tanos, V., Prus, D., Weinstein, D., **Tykocinski, M.L.**, de-Groot, N., Hochberg, A., Ariel, I. Expression of the imprinted H19 oncofetal RNA in epithelial ovarian cancer. *European Journal of Obstetrics, Gynecology, & Reproductive Biology.* 85: 7-11, 1999.
57. Fayen, J. D., and **Tykocinski, M. L.** The expansion of human gamma-delta T cells in response to Daudi cells requires the participation of CD4+ T cells. *Immunology*, 97: 272-279, 1999.
58. Brunschwig, E.B., Fayen, J.D., Medof, M.E., and **Tykocinski, M. L.** Protein transfer of glycosyl-phosphatidylinositol (GPI)-modified murine B7-1 and B7-2 costimulators. *J. Immunother*, 22: 390-400, 1999.
59. Ohana, P., Kopf, E., Bibi, O., Ayesh, S., Schneider, T., Laster, M., **Tykocinski, M. L.**, de Groot, N., Hochberg, A. The Expression of the H19 Gene and its Function in Human Bladder Carcinoma Cell Lines. *FEBS Letters.* 454: 81-4, 1999.
60. Chen, A., Zheng, G., and **Tykocinski, M.L.** Hierarchical Costimulator Thresholds for Distinct Immune Responses: Application of a Novel two-step Fc Fusion protein transfer method. *Journal of Immunology*, 164: 705-711, 2000.
61. Geho, David H., Fayen, John D., Jackman, Robin M., Moody, Branch D., Porcelli, Steven A., and **Tykocinski, M. L.** Glycosyl-Phosphatidylinositol Reanchoring Unmasks



- Distinct Antigen-Presenting Pathways for CD1b and CD1c. *Journal of Immunology*, 165: 1272-1277, 2000.
62. Riley, G., J. Rachmilewitz, P. Koo, and **M. L. Tykocinski**.  $\alpha$ 2-Macroglobulin modulates the immunoregulatory function of the lipocalin placental protein 14. *Biochem. J.*, 351: 503-508, 2000.
63. Jui-Han Huang and **M. L. Tykocinski**. CTLA-4-Fas ligand functions as a *trans* signal converter protein in bridging antigen-presenting cells and T cells. *International Immunology*. 13, No. 4: 529-539, 2001.
64. Jui-Han Huang and **M. L. Tykocinski**. CTLA-4-Fas ligand Functions as a Trans Signal Converter Protein in Bridging Antigen-Presenting Cells and T Cells. *International Immunology* 13: 529-539, 2001.
65. Premkumar, Daniel R. D., Y. Fukuoka, D. Sevillever, E. Brunschwig, T. R. Rosenberry, **M. L. Tykocinski**, and E. Medof. Properties of Exogenously Added GPI-Anchored Proteins Following Their Incorporation Into Cells. *Journal of Cellular Biochemistry*, 2001.
66. Xiong, N., Mao, J., Chakraborty, S., Eshleman, S., and **Tykocinski, M.L.** Effects of N-glycosylation on secretion and immunosuppressive function of placental protein 14 (glycodelin). Submitted, 2001.
67. Mao, J., Geho, D., Chakraborty, S., Feng, Y., Anderson, V., Shoham, M., and **Tykocinski, M.L.** Retinoid binding potential of two placental protein 14 variants. Submitted, 2001.
68. Rachmilewitz, J. and **Tykocinski, M.L.** T cell activation threshold is elevated by an immunoregulatory lipocalin. Submitted, 2001.
69. Weber, M.C., Ziats, N.P., Chen, A., Ratnoff, O.D., **Tykocinski, M.L.**, Riely, G. Inhibition of Factor XII (Hageman Factor) Activation by the Immunosuppressive Protein PP14. In preparation, 1999.
70. Xiong, N., Mao, J., Feng, Y., Chakraborty, S., and **Tykocinski, M.L.** Secretory properties of two placental protein 14 variants. In preparation, 2001.
71. Xiong, N., Weber, M., and **Tykocinski, M.** Placental protein 14 (glycodelin) is secreted from activated platelets. In preparation, 2001.
72. Chen, A., Fayen, J., Trefzer, U., Brunschwig, E., and **Tykocinski, M.L.** Poly-histidine tagged glycosyl-phosphatidylinositol-modified human B7-1 retains costimulator function. In preparation, 2001.
73. Riely, G., Koo, P. Chakraborty, S. and **Tykocinski, M.L.** Placental protein 14 binds to the serum transporter alpha-2 macroglobulin. Submitted, 2001.

[Over 10 additional manuscripts in preparation.]

Abstracts:

- Weber, M.C. and Tykocinski, M.L. Use of episomal vectors for antisense RNA-mediated inhibition of ICAM-1 in human bone marrow stromal cells. J. Cell. Biochem. Suppl. 17E:199, 1993.
- Fayen, J., Huang, J.H., Meyerson, H., Zhang, D., Getty, R., Chu, R., Kaplan, D., Greenspan, N., and Tykocinski, M.L. Soluble human CD8 binds to a recombinant fusion protein which incorporates the class I MHC alpha3 domain. AAI, Denver, CO, 21-25 May 1993. 288A:1647.
- Feng, Y., Morrow, D.M., and Tykocinski, M.L. A novel hematopoietic isoform of placental protein 14 (PP14). AAI, Denver, CO; 21-25 May 1993. J. Immunol. 203A:1155
- Srisuchart, B., LaCell, K.A., Tykocinski, M.L., Kaplan, D.R. CD8-dependent immunoregulation in a murine *in vivo* model. AAI, Denver, CO; 21-25 May 1993. 280A:1602.
- Tsao, H.M., Kaplan, D., and Tykocinski, M.L. Molecular dissection of the human CD8 molecule. AAI, Denver, CO; 21-25 May, 1993. 288A:1649.
- Meyerson, H., Fayen, J. Kaplan, D., and Tykocinski, M.L. The immunoglobulin light chain variable (Ig-V) homology domain of CD8 can mediate binding to class I MHC molecules. AAI, Denver, CO; 21-25 May 1993. 288A:1648
- Singh, N., Zoeller, R.A., Tykocinski, M.L., Lazarow, P.B. and Tartakoff, A.M. The addition of lipid substituents of mammalian protein glycosyl phosphoinositol anchors. American Society for Cell Biology 3rd annual meeting, New Orleans, December, 1993.
- Trojan, J., Johnson, T.R., Rudin, S.D., Blossey, B.K., Shevelev, A., Abdul-Karim, F.W., Anthony, D.D., Tykocinski, M.L., Ilan, Ju., and Ilan, Jo. Gene therapy of murine teratocarcinoma, American Association for Cancer Research, Inc., January, 1994.
- Brunschwig, E. and Tykocinski, M. Glycosyl-phosphatidylinositol-modified murine B7-1 retains costimulatory activity. Experimental Biology '95, Atlanta, GA, April, 1995.
- Meyerson, H., Huang, J.-H, Fayen, J., Getty, R., Greenspan, N., and Tykocinski, M. Functional dissociation of CD8's immunoglobulin homologue and connecting peptide domains. Experimental Biology '95, Atlanta, GA, April, 1995.
- Fayen, J. and Tykocinski, M. Purification of a glycosylphosphatidylinositol-modified form of human CD8 incorporating a polyhistidine tag. Experimental Biology '95, April, 1995.
- Fayen, J. Chen, A. and Tykocinski, M. Polyhistidine-tagging of glycosyl-phosphatidylinositol-modified costimulators. AACR, New Orleans, LA, 1996.
- Chen, A., Meyerson, H., and Tykocinski, M. Glycosylation is not required for B7-1 (CD80) association with its counter-receptors. AAI97, February, 1997.
- Riely, G.J., Koo, P.H., and Tykocinski, M.L. Interaction of placental protein 14 with  $\alpha_2$ -macroglobulin. AAI, San Francisco, 1998.
- Weber, M.C., and Tykocinski, M.L. Cloning and expression profiling of murine clk2 mRNA. AAI, San Francisco, 1998.
- Fayen, J., Huang, J.-H., and Tykocinski, M.L. Anti-MHC class II monoclonal antibodies inhibit the stimulation of  $\gamma\delta$  T cells by Daudi cells. AAI, San Francisco, 1998.
- Kopf, E., Bibi, O., Ayeah, S., Tykocinski, M.L., Vitner, K., Locijenga, L.H.J., deGroot, N., Hochberg, A. *The effect of retinoic acid on the activation of the human H19 promoter by a 3' downstream region.* FEBS Letters 432(3) August, 1998.

Editorials, Reviews, Chapters:

- Medof, M.E. and **Tykocinski, M.L.** The cytoplasmic extension as a determinant for glycoinositolphospholipid anchor substitution. *In Glycobiology*, Welply, J.K. and Jaworski, E. (eds.) Wiley-Liss, Inc., New York, pp. 17-22, 1990.
- Tykocinski, M.L.**, Hambor, J.E., Weber, M.C., Groger, R.K. and Kaplan, D.R. Antisense RNA analysis in lymphocytes: defining new functions for cell surface molecules (review article). *In Advances in Gene Technology: The molecular biology of immune diseases and the immune response*. Streilein, J.W., *et al.* (eds.), Oxford Univ. Press, ICSU Short Reports 10:128-129, 1990.
- Tykocinski, M.L.**, and Kaplan, D.R. A multifunctional perspective of the CD8 molecule. *In NK Cell Mediated Cytotoxicity: Receptors, signaling and mechanisms*. Lotzova, E., and Herberman, R.B. (eds.), Ann Arbor: CRC Press, pp. 393-408, 1992.
- Johnson, T.R., Trojan, J., Rudin, S.D., Ilan, Ju., **Tykocinski, M.L.**, and Ilan, J. Evoking an immune response to glioblastoma cells transfected with episome-based plasmid expressing antisense transcripts to insulin-like growth factor I. *Molecular Genetics of Nervous System Tumors*, Chapter 35, pp. 387-400, 1993 Wiley-Liss, Inc.
- Tykocinski, M. L.**, Na Xiong, Dwight M. Morrow. Platelet Immunoregulatory Factors, in *Stem Cells: Thrombopoietin and Cytokine Regulation of Platelet Production*, AlphaMed Press, Volume 14, Supplement 1, pp. 240-245, 1996.
- Tykocinski, M.L.** Engineering cellular cancer vaccines: gene and protein transfer options, in *Gene Therapy of Cancer*, eds. Gerson, S., and Lattime, E., Academic Press, Chapter 19, pp. 301-318, 1998.

**EXHIBIT E****PROFESSIONAL ACTIVITIES****Executive Training Programs:**

- |      |  |
|------|--|
| 1999 | Program for Chiefs of Clinical Services, Harvard School of Public Health (Boston, MA)  |
| 1999 | Executive Development Seminar, AAMC Management Education Programs (Ft. Lauderdale, FL) |

**Editorial Positions:**

- |        |  |
|--------|--|
| 1989 - | Ad Hoc reviewer for Am. J. Pathol. J. Immunol. Methods, J. Virology J. Immunology, Cancer Res., Immunity, Annals of Neurology, Blood, J. Clinical Invest., Am. J. of Surg. Pathol. |
| 1996 - | Editorial Board, American Journal of Pathology   |

**Academic Committees:****Case Western Reserve University:**

- |         |   |
|---------|---|
| 1984-90 | Codirector, Immunology Research Seminar Series (University Hospitals of Cleveland, sponsored by Dept. of Pathology) |
| 1985-98 | Faculty Member, Medical Sciences Training Program, CWRU, NIH-funded   |
| 1988    | Member, Search Committee for Director of Division of Human Genetics, CWRU   |
| 1988-91 | At-large preclinical representative, Faculty Council, CWRU  |
| 1989-90 | Member, Search Advisory Committee for Dean of Medicine and Vice-President for Medical Affairs, CWRU                 |
| 1988-95 | Codirector, Immunology Seminar Series, CWRU   |
| 1990-95 | Member, Research Committee, CWRU School of Medicine   |
| 1990-91 | Member, Steering Committee, Faculty Council, CWRU School of Medicine  |
| 1990-95 | Member, Department of Pathology Committee on Appointment Promotion and Tenure, CWRU                                 |
| 1991-95 | Chairman, Department of Pathology Committee on Appointments, Promotion and Tenure, CWRU                             |
| 1991    | Judge, PEW Scholars Program in Biomedical Sciences  |
| 1991-94 | Senator, University Faculty Senate, CWRU  |
| 1991-98 | Member, Executive Council, CWRU Cancer Center   |
| 1993-94 | Member, Pathology Faculty Search Committee, CWRU  |
| 1994-95 | Member, CWRU School of Medicine Conflict of Interest Committee  |
| 1996-98 | Member, CWRU School of Medicine Technology Transfer Committee   |
| 1997-98 | Member, Outreach Seminar Program, CWRU  |

- 1998 Member, Nominating Committee, School of Medicine, CWRU
- 1998 Member, Millenium Research Planning Committee (appointed by Dean), CWRU School of Medicine
- 1998 Member, Search Committee for Chairperson, Department of Biochemistry, CWRU

University of Pennsylvania Health System:

- 1998-99 Member, Clinical Practice Executive Committee (CPEC)
- 1998-99 Member, Steering Committee of the Standing Committee of Department Chairs (appointed by Dean/CEO)
- 1998 - Member, Administrative Forum
- 1998 - Member, CPEC Finance Subcommittee
- 1998 - Member, Clinical Chairs and Chiefs Advisory Committee
- 1998 - Member, Medical Board
- 1998 - 2000 Member, Enterprise Master Patient Index Steering Committee
- 1998 - Member, Standing Committee of Department Chairs
- 1998 - Member, Basic Science Chairs
- 1998 - 2000 Member, Information Management Planning Council
- 1999 - Member, Clinical Practices of the University of Pennsylvania (CPUP) Board of Directors (formerly CPEC)
- 1999 - Member, Executive Committee, CPUP
- 1999 - 2000 Member, Hunter Group Physicians Advisory Work Group
- 1999 - Member, Academic Review Committee (appointed by Dean/CEO)
- 1999 - Member, Cancer Center Translational Research Committee
- 2000 Member, Arthur Andersen Consultation Committee (appointed by Dean/CEO)
- 2000 - Member, Steering Committee of the Standing Committee of Department Chairs (appointed by Dean/CEO)
- 2000 - Chair, Basic Science Chairs

University of Pennsylvania Department of Pathology and Laboratory

Medicine:

- 1998 - Member, Committee on Appointments and Promotions
- 1998 - Chair, Executive Committee
- 1998 - Chair, Section Chiefs Committee

Major Teaching and Clinical Responsibilities:

Case Western Reserve University:

- 1985-98 Lecturer, Biological Basis of Diseases (first-year medical students), CWRU School of Medicine
- 1985-90 Subject Committee Chairman, Immunology Component of Biological Basis of Disease I, CWRU School of Medicine
- 1985-90 Member, Review Committee for interim and comprehensive examinations in Biological Basis of Disease I, CWRU

- 1985-98 Course Organizer and Lecturer, Advanced Molecular Immunology (graduate level course), CWRU
- 1985-98 Lecturer, Advanced Immunobiology (graduate level course), CWRU
- 1985-98 Lecturer, Immunology of Infectious Disease (graduate level course), CWRU
- 1986-98 Lecturer, Fundamental Immunology, (undergraduate level course), CWRU
- 1986-98 Lecturer, Immunopathology, (graduate level course), CWRU
- 1986-96 Lecturer, "Molecular Biology in medicine," (for incoming Pediatric Fellows), University Hospitals of Cleveland
- 1990-98 Guest lecturer (annual) immunology course, Northeastern Ohio Universities College of Medicine, Rootstown, OH

University of Pennsylvania:

- 1998- Director, Clinical Laboratories of the Department of Pathology and Laboratory Medicine

Advisory Boards:

- 1999- Scientific Advisory Board  
A.J. Renner & Associates Biotechnology Advantage Program (Illinois)

Lectures by Invitation:

- Spring 1983 Plenary Speaker, International Workshop on Major Histocompatibility Genes (Airlie House, VA)
- Spring 1985 Invited Speaker, Research Seminar Series at the Cleveland Clinic (Cleveland, OH)
- Fall 1986 Invited Speaker, MIT Workshop on "Complement genes" (Boston, MA)
- Fall 1987 Plenary Speaker, EMBO Workshop on "Post-translational Modification of Proteins by Lipids" (Les Diablerets, Switzerland)
- Winter 1988 Invited Speaker, Research Seminar Series at Rockefeller University (New York, NY)
- Winter 1988 Invited Speaker, NIH Immunology Research Seminar Series (Bethesda, MD)
- Spring 1988 Invited Speaker, American Association of Cancer Research minisymposium on "Regulation of Gene Expression" (New Orleans, LA)
- Fall 1988 Molecular Biology Seminar Series at Roswell Park Memorial Institute (Buffalo, NY)
- Winter 1989 Plenary Speaker, UCLA Symposium on "Glycobiology" (Frisco, CO)

Spring 1989	Invited Speaker, Immunology Seminar Series at Cleveland Metropolitan General Hospital (Cleveland, OH)
Summer 1989	Invited Speaker, 7th International Congress of Immunology - Workshop on "Genes for Accessory Molecules of the T Cell Receptor" (Berlin, W. Germany)
Fall 1989	Invited Speaker, Pathology Seminar Series at New York University School of Medicine (New York, NY)
Fall 1989	Invited Speaker, Immunology Seminar Series at Stanford Medical School (Palo Alto, CA)
Fall 1989	Invited Speaker, Research Seminar Series at University of Cincinnati Medical Center (Cincinnati, OH)
Winter 1990	Plenary Speaker, Miami Bio/Technology Winter Symposium on "Advances in Gene Technology: Molecular Basis of Immune Diseases" (Miami, FL)
Winter 1990	Plenary Speaker, UCLA Symposium on "Synthetic Peptides: Approaches to Biological Problems" (Frisco, CO)
Summer 1990	Plenary Speaker, 4th International Cell-Mediated Cytotoxicity Workshop (Oglebay Park, W. VA)
Fall 1990	Invited Speaker, Seminars in Cell Pathology at Cornell University (Ithaca, NY)
Fall 1990	Invited Speaker, Immunology Seminar Series at Mount Sinai School of Medicine (New York, NY)
Winter 1991	Invited Speaker, NIH Pathology B Study Section Workshop (Tamarron, CO) (Meeting Report in Cancer Research 51:5440-5444, 1991)
Spring 1991	Invited Speaker, 5th Annual Meeting of the CWRU Cancer Center; title: on "Gene Transfer and Therapy" (Cleveland, OH)
Spring 1991	Invited Speaker, Biochemistry Seminar Series at Hebrew University (Jerusalem, Israel)
Fall 1991	Invited Speaker, Special Research Seminar at the Center for Molecular Genetics, University of California - San Diego (San Diego, CA)
Fall 1991	Plenary lecture, Annual meeting of the Meridia-Suburban Medical Society (Cleveland, OH)

Fall 1991	Invited Speaker, Immunology Seminar Series at Memorial Sloan-Kettering (New York, NY)
Fall 1991	Invited Speaker, Immunology Seminar Series at University of California--San Francisco (San Francisco, CA)
Fall 1991	Invited Speaker, Biochemistry Seminar Series at CWRU (Cleveland, OH)
Fall 1991	Invited Speaker, Research Seminar Series at the Cleveland Clinic (Cleveland, OH)
Spring 1992	Invited Speaker, Immunology Seminar Series at University of Washington (Seattle, WA)
Spring 1992	Plenary Speaker, International Congress on "Molecular Approaches to Nephrology: Prospects in Diagnosis and Management"; Chair of round table on "Molecular Aspects of Renal Transplantation" (Bari, Italy)
Spring 1992	Invited Speaker, Immunology Seminar Series at the Cleveland Clinic (Cleveland, OH)
Fall 1992	Invited Speaker, Seminar Series in the Pharmacological Sciences, CWRU (Cleveland, OH)
Fall 1992	Invited Speaker, Pathology Research Seminar at the University of Washington (Seattle WA)
Fall 1992	Invited Speaker, Research Seminar at Brown University (Providence, RI)
Fall 1992	Plenary Speaker, 45 <sup>th</sup> Annual Symposium on Fundamental Cancer Research entitled "Immunobiology of Cancer: Cellular and Molecular Mechanisms" (Houston, TX)
Winter 1993	Invited Speaker, Research Seminar at Northeastern Ohio Universities College of Medicine, Department of Microbiology and Immunology (Rootstown, OH)
Spring 1993	Invited Speaker, Immunobiology Seminar Series at Yale University (New Haven, CT)
Spring 1993	Invited Guest of People's Republic of China; 14-day lecture tour in three Chinese cities (Shanghai, Xi'an, and Beijing)
Summer 1993	Plenary Speaker, International Symposium on "Tumors of the Central Nervous System" (Milan, Italy)
Fall 1993	Invited Speaker and consultant, Agracetus, Inc. (Madison, WI)



Winter 1994	Cleveland Cancer Group, Cleveland Clinic (Cleveland, OH)
Winter 1994	Skin Diseases Research Center (Cleveland, OH)
Winter 1994	Biochemistry Seminar Series (Cleveland, OH)
Spring 1994	Visiting Scientist, Department of Biochemistry, Hebrew University (Jerusalem, Israel)
Summer 1994	Plenary Speaker, Biotech 94 Conference, sponsored by the State of Ohio's Edison Biotechnology Center (Columbus, OH)
Winter 1995	Co-chairperson, Mini-Symposium entitled "Lessons from Hematopoietic Malignancies" at the Sixth International Workshop on Chromosomes in Solid Tumors, Feb. 19-21, 1995 (Tucson, AZ)
Spring 1995	Co-chairperson, Poster Discussion Session entitled "Gene Therapy I" at the 86th Annual Meeting of the American Association of Cancer Research, March 18-22, 1995 (Toronto, Canada)
Spring 1995	Plenary Speaker, Mini-symposium on Antisense Gene Therapy, ECOG (Eastern Cooperative Oncology Group) meeting (Denver, CO)
Spring 1995	Plenary Speaker, Warner-Lambert/Parke-Davis Award lecture, Experimental Biology '95 Meeting (Atlanta, GA)
Summer 1995	Invited Speaker, Special course entitled "Transgenic Animals to Model Human Diseases of the Nervous System" at the Annual Meeting of the American Association of Neuropathologists, June 7, 1995 (San Antonio, TX)
Fall 1995	Plenary Speaker, Symposium entitled "Gene Therapy for Immune Deficiencies and Cancer" to commemorate the 5th anniversary of the first human gene therapy clinical trial (Cleveland, OH)
Fall 1995	Research Seminar at Mayo Clinic (Jacksonville, FL)
Fall 1995	Pathology Seminar at Emory University (Atlanta, GA)
Fall 1995	Plenary Speaker, Amici Medicinae program entitled: "Genes: New Weapons to Fight Cancer and Arteriosclerosis" (Cleveland, OH)
Winter 1996	Plenary Speaker, Keystone Symposium on Molecular and Cellular Biology entitled "Molecular Regulation of Platelet Production" (Taos, NM)

Winter 1996	Plenary Speaker, Keystone Symposium on Molecular and Cellular Biology entitled "Exploring and Exploiting Antibody and Ig Superfamily Combining Sites" (Taos, NM)
Spring 1996	Cancer Research Seminar, Karmanos Cancer Institute, Wayne State University (Detroit, MI)
Spring 1996	Immunology Seminar Series at Johns Hopkins, University (Baltimore, MD)
Spring 1996	Co-chairperson, Poster Discussion Session entitled "Developing Effective Gene Therapy: Promising Strategies and Vectors" at the 87th Annual Meeting of the American Association of Cancer Research, April 20-24, 1996 (Washington, DC)
Spring 1996	Plenary Speaker, The 13th International Hammersmith Conference, May 27-30, 1996 (Crete, Greece)
Summer 1996	Research Seminar at Tulane Medical School (New Orleans, LA)
Winter 1997	Rammelkamp Research Seminar, MetroHealth Medical Center (Cleveland, OH)
Winter 1997	Co-Chairperson, Poster Discussion Session, Keystone Symposium on Molecular and Cellular Biology entitled "Cellular Immunology and the Immunotherapy of Cancer-III" (Copper Mountain, CO)
Winter 1997	Research Seminar at the Institute of Human Genetics, University of Minnesota (Minneapolis, MN)
Spring 1997	Research Seminar at the Public Health Research Institute (New York, NY)
Spring 1997	Immunology Seminar Series at CWRU (Cleveland, OH)
Fall 1997	Plenary Speaker, Meeting on "Regulation of Cell Growth and Cell Death" held at Mohican State Park Conference Center, Sept. 24-25, 1997 (Perrysville, OH)
Fall 1997	Plenary Speaker, International Meeting on "Interaction of GPI anchors with Biological Membranes," Sept. 14-17, 1997 (Splügen, Switzerland)
Fall 1997	Plenary Speaker, President's Weekend for Leading CWRU Alumni (Cleveland, OH)
Fall 1997	Pathology Research Seminar at University of Pennsylvania (Philadelphia, PA)

Winter 1998	City-Wide GI Grand Rounds entitled "Frontiers in Gastroenterology and Hepatology" (Cleveland, OH)
Spring 1998	Plenary Speaker, Molecular Virology Program Retreat on "Gene Therapy Initiatives," Ireland Cancer Center (Cleveland, OH)
Fall 1998	Featured Speaker, Biomedical Graduate Studies Convocation, University of Pennsylvania (Philadelphia, PA)
Fall 1998	Melanoma Group Seminar, Wistar Institute (Philadelphia, PA)
Fall 1998	Plenary Speaker, Institute for Human Gene Therapy 6 <sup>th</sup> Annual Retreat, University of Pennsylvania (Absecon, NJ)
Winter 1999	Physician Scholar Seminar Series, "The Altered Immunological State of Pregnancy: From Clinical Observations to Protein Pharmaceuticals" University of Pennsylvania (Philadelphia, PA)
Winter 1999	Research Seminar at Institute for Medicine and Engineering Seminar Series, University of Pennsylvania (Philadelphia, PA)
Winter 1999	Pathology Grand Rounds, Hospital of the University of Pennsylvania (Philadelphia, PA)
Summer 1999	Plenary Speaker, Association of Pathology Chairs, PRODS Meeting, Session on "Research by Residents: Issues of Funding and Organization" (Boulder, CO)
Fall 1999	Duhring Lecture Series, Department of Dermatology, Hospital of the University of Pennsylvania (Philadelphia, PA)
Fall 1999	Keynote Speaker, Third Joint International Cancer Conference (Capri, Italy)
Fall 1999	Mount Sinai-NYU, Medical Center and Health System, Tisch Hospital Grand Rounds, (New York, NY)
Fall 1999	New York University Medical Center, School of Medicine, Pathology Grand Rounds (New York, NY)
Winter 2000	Quest Distinguished Visiting Professor of Pathology, and Pathology Grand Rounds, John Hopkins University School of Medicine (Baltimore, MD)
Spring 2000	Plenary speaker, Annual Meeting of the Pennsylvania Association of Pathologists: "Pathology in the Millennium: Our past, our future!" (Valley Forge, PA)

- |             |   |
|-------------|---|
| Spring 2000 | Plenary speaker, Gene Therapy Workshop, Hadassah Florida Central Region Spring Conference (Orlando, FL)   |
| Spring 2000 | Plenary speaker, Pennsylvania Association of Pathologists Annual Meeting, May 6-7, 2000 (Valley Forge, PA)  |
| Spring 2000 | Co-Chair, Block Symposium on "Immune-based Therapy in Cancer," AAI/CIS Joint Annual Meeting, <i>Immunology 2000</i> (Seattle, WA)                               |
| Summer 2000 | APC/PRODS Annual Meeting with Pathology Department Administrators, Ivory Tower, Inc. "Leader Breakout Session on Research--Mixing Fun and Profit" (Boulder, CO) |
| Summer 2000 | University of Pittsburgh, Department of Pathology Seminar (Pittsburgh, PA)  |
| Winter 2001 | Pluto Society - American Association of University Pathologists (Maui, HI)  |

Organizing Roles in Scientific Meetings:

- |      |   |
|------|---|
| 1992 | Organizer, First Annual Immunology Research Workshop, Institute of Pathology, CWRU, held at Gwinn Estate  |
| 1992 | Member, Program Planning Committee for the 6 <sup>th</sup> Annual Retreat of The CWRU Cancer Research Center, "Developments in Molecular and Clinical Neuro-oncology" |

Patents:

Tykocinski, Mark L.: Method of reducing cellular immune responses involving T-cells using CD8-bearing antigen presenting cells. U.S. Patent Number 5,242,687, 1993

Tykocinski, Mark L.: CD8 derivatives and methods of use for cellular modulation and enhancements of cellular engraftment. U.S. Patent Number 5,601,828, 1997.

*Six U.S. patent applications pending with over twenty other associated continuances-in-part and foreign patent filings (relating to therapies for cancer, alloimmune and autoimmune diseases, and acute inflammatory conditions).*